

Faculty of Chemistry¹ and Faculty of Medicine², Vilnius University, Vilnius, Lithuania

Synthesis of 6,7-dialkoxy-2-arylmethylidene-2,3-dihydrobenzo[4,5]-imidazo[2,1-*b*][1,3]thiazol-3-ones exhibiting anti-inflammatory activity

L. LABANAUSKAS¹, A. BRUKŠTUS¹, E. UDRĖNAITĖ², P. GAIDELIS², V. BUČINSKAITĖ¹ and V. DAUKŠAS¹

New 6,7-dialkoxy-2-arylmethylidene-2,3-dihydrobenzo[4,5]imidazo[2,1-*b*][1,3]thiazol-3-ones (**3a–h**, **4b**, **c**, **e**, **g**) were synthesized from 2-(5,6-dialkoxy-1*H*-benzo[*d*]imidazol-2-ylsulfanyl)acetic acids (**1**, **2**) and corresponding aromatic aldehydes in acetic anhydride. The compounds **3e**, **f** and **4b**, **g** were also synthesized from corresponding aromatic aldehydes and 6,7-dialkoxy-2,3-dihydrobenzo[4,5]imidazo[2,1-*b*][1,3]thiazol-3-ones (**5**, **6**) obtained by the cyclization of the acids **1** and **2** in acetic anhydride. The synthesized compounds **3a–h** and **4b**, **c**, **e**, **g** exhibit anti-inflammatory activity.

1. Introduction

Following reports of anti-inflammatory activity of 6-arylmethylidene-3-(2-pyrimidinyl)-5,6-dihydro[1,3]thiazolo[2,3-*c*][1,2,4]triazol-5-ones [1] the series of compounds containing similar structure – 6,7-dialkoxy-2-arylmethylidene-2,3-dihydrobenzo[4,5]imidazo[2,1-*b*][1,3]thiazol-3-ones (**3a–h**, **4b**, **c**, **e**, **g**) were synthesized and investigated for anti-inflammatory activity.

2. Investigations, results and discussion


The target 6,7-dialkoxy-2-arylmethylidene-2,3-dihydrobenzo[4,5]imidazo[2,1-*b*][1,3]thiazol-3-ones (**3a–h**, **4b**, **c**, **e**, **g**) were synthesized by the reaction of the 2-(5,6-dialkoxy-1*H*-benzo[*d*]imidazol-2-ylsulfanyl)acetic acids (**1**, **2**) [2] with aromatic aldehydes in acetic anhydride. Some of these compounds (**3e**, **f**, **4b**, **g**) were also obtained by the reaction of corresponding aromatic aldehydes with the

Table 1: Experimental, physico-chemical and spectral data for compounds 3a–h and 4b, c, e, g

| Compd. | Formula | Yield (%) (from 1 , 2 / from 5 , 6) | M.p. (°C) | UV: λ_{\max} (nm), (lg ϵ) | IR: $\nu_{\text{C=O}}$ (cm^{-1}) | ¹ H NMR | | | | |
|-----------|--|--|--------------|--|--|--|--------|--------|--|--------|
| | | | | | | RO | 5-H | 8-H | Ar-H | =CH |
| 3a | C ₁₈ H ₁₄ N ₂ O ₃ S | 78 | 286–287 | 291 ^a , 311(3.32), 335 ^a , 382 ^a | 1724 | s ^b 3.67 and 3.72 CH ₃ O | s 7.00 | s 7.52 | s 7.22 | s 8.11 |
| 3b | C ₁₈ H ₁₃ FN ₂ O ₃ S | 58 | 275–278 | 288(3.69), 314(3.78), 330 ^a , 390 ^a | 1710 | s 3.87 and 3.92 CH ₃ O | s 7.15 | s 7.45 | m ^c 7.24–7.31, 7.71–7.76 and 7.92–7.99 | s 8.06 |
| 3c | C ₁₆ H ₁₂ N ₂ O ₄ S | 54 | 259–262 | 279(3.87), 288(3.80), 360(4.15) | 1712 | s 3.68 and 3.72 CH ₃ O | s 7.01 | s 7.47 | m 6.30–6.45, 6.82–7.04 and 7.38–7.62 | s 7.85 |
| 3d | C ₁₇ H ₁₄ N ₂ O ₄ S | 49 | 251–252 | 280(3.16), 288(3.18), 373(3.41) | 1711 | s 3.67 and 3.72 CH ₃ O | s 7.00 | s 7.50 | m 6.02–6.18 and 6.83–7.08; s 2.17, CH ₃ | s 7.91 |
| 3e | C ₁₆ H ₁₂ N ₂ O ₃ S ₂ | 69/76 | 282–284 | 278 ^a , 284(3.65), 358(3.73) | 1700 | s 3.67 and 3.72 CH ₃ O | s 7.00 | s 7.52 | m 6.78–7.73 | s 8.17 |
| 3f | C ₁₇ H ₁₃ N ₃ O ₃ S | 75/81 | 284–285 | 288 ^a , 321(3.59), 321(3.59) | 1716 | s 3.72 and 3.80 CH ₃ O | s 7.19 | s 7.44 | s 7.44, m 7.65–7.94 and 8.78–8.86 | s 8.10 |
| 3g | C ₁₇ H ₁₃ N ₃ O ₃ S | 55 | 285–286 | 305(3.49), 400(2.75) | 1716 | s 3.68 and 3.72 CH ₃ O | s 7.07 | s 7.46 | m 7.92–8.99 | s 8.99 |
| 3h | C ₁₇ H ₁₃ N ₃ O ₃ S | 50 | 274–275 | 301(4.03), 400(3.02) | 1722 | s 3.88 and 3.92 CH ₃ O | s 7.18 | s 7.54 | m 7.82–8.80 | s 8.04 |
| 4b | C ₂₀ H ₁₇ FN ₂ O ₃ S | 51/67 | 312–315 | 291 ^a , 313(4.08), 335 ^a , 388 ^a | 1727 | t ^d 1.43 and 1.45 CH ₃ , k ^e 4.13 and 4.31 CH ₂ O | s 7.17 | s 7.45 | m 7.28–7.38 and 7.72–7.83 | s 8.08 |
| 4c | C ₁₈ H ₁₆ N ₂ O ₄ S | 64 | 247–249 | 290(3.00), 360(3.17) | 1716 | t 1.46 and 1.48 CH ₃ , k 4.08 and 4.13 CH ₂ O | s 7.10 | s 7.42 | m 6.65–6.70, 7.04–7.07 and 7.85–7.99 | s 8.01 |
| 4e | C ₁₈ H ₁₆ N ₂ O ₃ S ₂ | 67 | 239–242 | 289(2.81), 360(3.01) | 1711 | t 1.44 and 1.47 CH ₃ , k 4.09 and 4.12 CH ₂ O | s 7.12 | s 7.44 | m 7.24–7.28, 7.64–7.67 and 7.79–8.00 | s 8.27 |
| 4g | C ₁₉ H ₁₇ N ₃ O ₃ S | 54/71 | 243–244 | | 1718 | t 1.44 and 1.47 CH ₃ , k 4.09 and 4.12 CH ₂ O | s 7.09 | s 7.46 | m 7.90–8.39 | s 8.89 |

^a Shoulder, ^b Singlet, ^c Multiplet, ^d Triplet (J = 6 Hz), ^e Quartet (J = 6 Hz)

Scheme



1, 3a–h, 5: R = CH₃

2, 4b, c, e, g, 6: R = C₂H₅

3a–h, 4b, c, e, g: Ar = C₆H₅ (a), 4-FC₆H₄ (b), 2-furyl (c), 2-(5-methylfuryl) (d), 2-tienyl (e), 2-pyridyl (f), 3-pyridyl (g), 4-pyridyl (h)

6,7-dialkoxy-2,3-dihydrobenzo[4,5]imidazo[2,1-b][1,3]thiazol-3-ones (**5**, **6**) in acetic anhydride (scheme).

Compound **5** is known [3] and the new analogue **6** has been prepared by cyclisation of acid **2** in acetic anhydride. The yields of compounds **3e**, **f** and **4b**, **g** obtained from the acids **1** and **2** by the one-step synthesis were higher than those obtained by the two-step synthesis via isolation of the intermediate products **5** and **6** (51–78% and 45–65%, respectively).

The postulated structures of the newly synthesized compounds **3a–h**, **4b**, **c**, **e**, **g** and **6** are in agreement with their UV, IR and ¹H NMR spectral and elemental analysis data.

The means of $\nu_{C=O}$ in IR spectra of diethoxy derivatives **4b**, **c**, **e**, **g** are 2–17 cm⁻¹ higher than those of analogous dimethoxy derivatives **3b**, **c**, **e**, **g**. The means of λ_{max} in UV spectra of these compounds follow the same trend and the means of lg ϵ – the opposite trend. The means of the chemical shift of 5-H hydrogen atom in the ¹H NMR spectra of the compounds **3a–h** are more sensitive to the nature of the substituent Ar than those of 8-H hydrogen atom (the variations are 7.00–7.19 and 7.44–7.54 ppm, respectively). The means of the chemical shift of 5-H and 8-H hydrogen atoms in the spectra of the compounds **4b**, **c**, **e**, **g** keep the some tendention (Table 1).

Most of the compounds **3** and **4** possess anti-inflammatory activity comparable with that of acetylsalicylic acid and the compounds **3c**, **g**, **h** are more active than ibuprofen. The anti-inflammatory activity of dimethoxy derivatives was equal to that of analogous diethoxy derivatives (in the case of the compounds **3b** and **4b**), or higher (in the case of the compounds **3c** and **4c**, **3e** and **4e**, **3g** and **4g**). The

acute toxicity (LD₅₀) of the compounds **3c**, **g**, **h** was less than that of acetylsalicylic acid and significantly less than that of ibuprofen (Table 2).

3. Experimental

3.1. Chemistry

M.p.'s were determined in open capillaries and are uncorrected. The UV spectra were recorded on a Lambda 20 (Perkin-Elmer, Sweden), IR spectra – on a Spectrum BX FT-IR (Perkin-Elmer, Sweden) in nujol and ¹H NMR spectra – on a BS–587A (80 MHz, Tesla, Czechoslovakia) in CDCl₃ with TMS as an internal standart. Chemical shifts (δ) are reported in ppm, coupling constants (J) are given in Hz. All new compounds were analyzed for C, H and N and the results were in an acceptable range.

2-(5,6-Dialkoxy-1H-benzo[d]imidazol-2-ylsulfanyl)acetic acids (**1**, **2**) [2] and 6,7-dimethoxy-2,3-dihydrobenzo[4,5]imidazo[2,1-b][1,3]thiazol-3-one (**5**) [3] were synthesized by the known methods.

3.1.1. 6,7-Dialkoxy-2-arylmethylidene-2,3-dihydrobenzo[4,5]imidazo[2,1-b][1,3]thiazol-3-ones (**3a–h**, **4b**, **c**, **e**, **g**)

A mixture of 0.83 g (0.01 mol) anh. sodium acetate, 0.01 mol 2-(5,6-dialkoxy-1H-benzo[d]imidazol-2-ylsulfanyl)acetic acid (**1** or **2**) or 6,7-dialkoxy-2,3-dihydrobenzo[4,5]imidazo[2,1-b][1,3]thiazol-3-one (**5** or **6**), 0.015 mol of the corresponding aromatic aldehyde and 15 ml acetic anhydride was heated at 100 °C for 0.5 h. Then the reaction mixture was cooled and the precipitate obtained was recrystallized from dimethylformamide (Table 1).

3.1.2. 6,7-Diethoxy-2,3-dihydrobenzo[4,5]imidazo[2,1-b][1,3]thiazol-3-one (**6**)

A mixture of 20 ml acetic anhydride, 5 ml pyridine and 1.2 g (0.004 mol) 2-(5,6-diethoxy-1H-benzo[d]imidazol-2-ylsulfanyl)acetic acid (**2**) was heated at 90 °C for 0.5 h, cooled and poured into water. The precipitate was filtered off and recrystallized from ethanol. Yield: 0.75 g (67%), m.p.: 165–167 °C. ¹H NMR: 1.47 (t (6Hz), 6H, CH₃), 4.08 (k (6Hz), 4H, OCH₂), 4.31 (s, 2H, SCH₂), 7.10 (s, 1H, Ar-H), 7.44 (s, 1H, Ar-H). IR (cm⁻¹): 1732 (C=O). UV [λ_{max} (lg ϵ)]: 250 (3.31), 302 (2.89). C₁₃H₁₄N₂O₃S.

3.2. Pharmacology

Adult male Wistar strain rats weighing 180–220 g and male BALB/C strain mice weighing 18–22 g were used. The animals were allowed food and water *ad libitum*. They were housed in rooms at 18–20 °C with a 12 h light/dark cycle and relative humidity of 55–60%. The animals were randomly allocated into groups at the beginning of all the experiments. All test compounds and the reference drugs were administered orally suspended in 0.5% carboxymethylcellulose solution. Carrageenin-induced hind-paw oedema in rats was produced by the method of Winter et al. [4]. Carrageenin solution (1.0% in sterile 0.9% NaCl solution) in a volume of 0.1 ml was injected subcutaneously into the subplantar region of the right hind paw 1 h after the administration of the test compound. Control animals received only 0.5% carboxymethylcellulose solution. Right hind paw

Table 2: Anti-inflammatory activity (50 mg/kg p.o.) and acute toxicity (LD₅₀) data for compounds **3a–h** and **4b**, **c**, **e**, **g**

| Compd. | 0.1 ml of 1% carrageenin solution | | 0.1 ml of 5% bentonite suspension | | LD ₅₀ (mg/kg) |
|----------------------|---|---|---|---|-----------------------------|
| | Cross-section of rat paw (relative units) | Inhibition of rat paw oedema (%) over control | Cross-section of rat paw (relative units) | Inhibition of rat paw oedema (%) over control | |
| Control | 45.01 | 0 | 43.10 | 0 | |
| 3a | 41.22 | 8.4 | 39.72 | 7.9 | |
| 3b | 33.70 | 25.2 | 31.77 | 26.3 | 2780 |
| 3c | 31.86 | 29.2 | 21.47 | 50.2 | >2000 |
| 3d | 39.83 | 11.5 | 38.58 | 10.5 | |
| 3e | 33.60 | 25.4 | 28.31 | 34.2 | >2000 |
| 3f | 41.90 | 7.3 | 39.57 | 8.2 | |
| 3g | 25.74 | 42.8 | 27.59 | 36.0 | 2545 |
| 3h | 26.33 | 41.5 | 28.36 | 34.2 | >2000 |
| 4b | 33.44 | 25.7 | 31.51 | 26.9 | |
| 4c | 34.70 | 22.9 | 35.69 | 17.2 | |
| 4e | 33.80 | 24.5 | 35.91 | 16.7 | |
| 4g | 34.38 | 23.6 | 34.27 | 20.5 | |
| Acetylsalicylic acid | 36.09 | 19.8 | 33.80 | 21.6 | 1216 |
| Ibuprofen | 27.10 | 38.0 | 34.18 | 20.7 | 500 |

volume was measured with an electronic onkograph immediately before and 1, 2, 3, and 5 h after the carrageenin injection. The increase observed was compared with that of control rats. Each experiment was made with 5 groups of rats, 10 animals each (the first one served as control). Bentonite-induced hind paw oedema was analogously studied [5]. Bentonite suspension (5% in sterile 0.9% NaCl solution) in a volume of 0.1 ml was used. The data were evaluated statistically using Student's t-test. A level of $p < 0.05$ was adopted as the test of significance. The tests of acute toxicity of the compounds were done on mice fasted for 24 h, water *ad libitum*. Groups of 6 mice were treated perorally with the test compound at various dose levels. The animals were watched for mortality and symptoms until day 8 [6].

References

- 1 Mekuškienė, G.; Vainilavičius, P.; Gaidelis, P.; Udrėnaitė E.: *Pharmazie* **53**, 94 (1998)
- 2 Labanauskas, L.; Brukštus, A.; Gaidelis, P.; Udrėnaitė, E.; Daukšas, V.: *Khim.-Pharm. Zh.* **32(2)**, 15 (1998)
- 3 Narayan, S.; Kumar, V.; Pujari H. K.: *Indian J. Chem.* **25B**, 267 (1986)
- 4 Winter, C. A.; Risley, E. A.; Nuss, G. W.: *Proc. Soc. Exp. Biol. Med.* **3**, 544 (1962)
- 5 Jedzinsky, J. J.: *Acta Univ. Palack. Olomouciensis fac. Med.* **103**, 175 (1982)
- 6 Litchfield, J. T.; Wilkoxon, F. J.: *Pharmacol. Exp. Ther.* **96**, 99 (1949)

Received November 1, 1999
Accepted December 18, 1999

Dr. Linas Labanauskas
Faculty of Chemistry
Vilnius University
Naugarduko 24
2006 Vilnius
Lithuania
linas.labanauskas@chf.vu.lt